AUTL Healthcare

Autolus Therapeutics plc

$1.41-0.35%

Price as of close on Nov 3, 2026 · Financials updated Nov 1, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United Kingdom
Market cap: 376.6M USD
Enterprise value: 542.8M USD
Full-time employees: 752

Overall health

Strength: growing faster than most peersgrowing faster than peers
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 2.14 vs a peer median of 0.63) and more debt relative to equity (4.91× vs a peer median of 0.22×)higher risk: bigger price swings (beta 2.14 vs peers 0.63) and more debt vs equity (4.91× vs peers 0.22×)

Ranks #995 of 1,157 healthcare companies (bottom 15%)

See how it ranks against its peers

Worth knowing

Much more borrowing than peers. Debt is 4.9× equity vs a peer median of 0.2×.Debt is 4.9× equity vs peers 0.2×.
Debt is 4.9× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 4.9× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Autolus Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.
Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -211%).
More volatile share price. Beta 2.14: tends to move more than the market.
Autolus Therapeutics's shares have swung more with the market than most peers' (beta 2.14, above the market's 1.0).

StockQuotient Score

29/ 100

Oct 5 29 → Nov 4 29

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-74.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-43.6%

Yahoo Finance fallback · SEC enterprise value unavailable (debt or EBITDA not reported in standard form) · trailing 12 monthsNegative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-61.8%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield19.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

96/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 26.7%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

The loss per share widened33% base weight · Z-score -1.20Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth130.0%

Yahoo Finance fallback · SEC figure unavailable or out of date · 3 fiscal years to Dec 2025Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growth292.2%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 10.15Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

10/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ ROA
▼ Operating margin
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-210.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -17.90Sector median: 0.0706 · MAD: 0.1217

Return on assets-56.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -10.90Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-36.9%

Yahoo Finance fallback · SEC operating income or invested capital unavailable · trailing 12 monthsReported value33% base weight · Z-score -4.15Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin15.7%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-374.3%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Higher

Higher relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Beta
▼ Debt / equity

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta2.14

Yahoo Finance · 5-year monthly beta vs the marketOutlier capped at sector 5th/95th percentile33% base weight · Z-score -4.28Sector median: 0.6250 · MAD: 0.3380

Current ratio4.89×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.66Sector median: 2.5860 · MAD: 1.3850

Debt / equity4.91×

Yahoo Finance fallback · no standard SEC debt tagOutlier capped at sector 5th/95th percentile33% base weight · Z-score -9.77Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Autolus Therapeutics

Is Autolus Therapeutics getting weaker?: Its latest SEC filing (Aug 11, 2026) showed no major changes. Its overall score is unchanged at 29/100 since Oct 28, 2026.
How is Autolus Therapeutics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -74.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -74.4% vs peers 1.5% (weaker than 100% of peers).
Is Autolus Therapeutics growing?: Yes, faster than most of its peers. Growth scores 96/100 against 1,393 healthcare peers. 3-year revenue growth 130.0% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 130.0% vs peers 5.8% (stronger than 95% of peers).
How profitable is Autolus Therapeutics?: Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Return on assets -56.8% vs a peer median of 1.7% (weaker than 95% of peers).Return on assets -56.8% vs peers 1.7% (weaker than 95% of peers).
How risky is Autolus Therapeutics?: Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.89× vs a peer median of 2.59× (stronger than 73% of peers).Current ratio 4.89× vs peers 2.59× (stronger than 73% of peers). Beta 2.14 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.14 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 11, 2026 · compared with the quarter ended Mar 31, 2026

No major changes

Worth watching: Autolus Therapeutics is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	92.6M USD	117.4M USD	+26.7%
Net income (12 months)	−289.0M USD	−280.2M USD	−3.0%
Operating margin	-285.9%	-210.8%	+75.1 pts
Free cash flow (12 months)	−286.8M USD	−232.7M USD	−18.9%
Cash	130.9M USD	171.4M USD	+30.9%
Shares outstanding	266.2M	266.2M	+0.0%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	—	—	100.0%	-12.5%	-27.8%	▼ 15 pts
Operating margin	—	—	-10583.1%	-2385.6%	-358.9%	▲ >999 pts
Net margin	—	—	-12272.3%	-2180.5%	-381.4%	▲ >999 pts
Return on assets (ROA)	-35.0%	-30.4%	-55.5%	-28.2%	-48.8%	▼ 21 pts
Return on equity (ROE)	-45.4%	-49.8%	-186.9%	-51.6%	-161.4%	▼ 110 pts
Free cash flow margin	—	—	-9221.0%	-2256.4%	-401.4%	▲ >999 pts
Current ratio	12.15×	9.18×	6.15×	10.88×	5.94×	▼ 45%
Quick ratio	—	—	6.15×	10.81×	5.48×	▼ 49%
Interest coverage	-127.65×	-16.10×	-3.99×	-25.98×	-7.38×	▲ 72%

AUTL price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: higher risk than most peers: its share price swings more than most peers’ (beta 2.14 vs a peer median of 0.63) and more debt relative to equity (4.91× vs a peer median of 0.22×)higher risk: bigger price swings (beta 2.14 vs peers 0.63) and more debt vs equity (4.91× vs peers 0.22×)

Ranks #995 of 1,157 healthcare companies (bottom 15%)

See how it ranks against its peers

Worth knowing

Much more borrowing than peers. Debt is 4.9× equity vs a peer median of 0.2×.Debt is 4.9× equity vs peers 0.2×.

Debt is 4.9× shareholders' equity, against a peer median of 0.2×, among the highest 10% of its peer group.Debt is 4.9× shareholders' equity, vs peers 0.2×, among the highest 10% of its peer group.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Autolus Therapeutics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Growing fast, still losing money. Revenue grew faster than 95% of peers, at an operating loss.

Revenue grew faster than 95% of peers, but the business runs at an operating loss (margin -211%).

More volatile share price. Beta 2.14: tends to move more than the market.

Autolus Therapeutics's shares have swung more with the market than most peers' (beta 2.14, above the market's 1.0).

Questions investors ask about Autolus Therapeutics

Is Autolus Therapeutics getting weaker?

Its latest SEC filing (Aug 11, 2026) showed no major changes. Its overall score is unchanged at 29/100 since Oct 28, 2026.

How is Autolus Therapeutics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -74.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -74.4% vs peers 1.5% (weaker than 100% of peers).

Is Autolus Therapeutics growing?

Yes, faster than most of its peers. Growth scores 96/100 against 1,393 healthcare peers. 3-year revenue growth 130.0% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 130.0% vs peers 5.8% (stronger than 95% of peers).

How profitable is Autolus Therapeutics?

Less profitable than most of its peers. Profitability scores 10/100 against 1,393 healthcare peers. Return on assets -56.8% vs a peer median of 1.7% (weaker than 95% of peers).Return on assets -56.8% vs peers 1.7% (weaker than 95% of peers).

How risky is Autolus Therapeutics?

Higher risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.89× vs a peer median of 2.59× (stronger than 73% of peers).Current ratio 4.89× vs peers 2.59× (stronger than 73% of peers). Beta 2.14 vs a peer median of 0.63 (weaker than 100% of peers).Beta 2.14 vs peers 0.63 (weaker than 100% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

92.6M USD

117.4M USD

+26.7%

Net income (12 months)

−289.0M USD

−280.2M USD

−3.0%

Operating margin

-285.9%

-210.8%

+75.1 pts

Free cash flow (12 months)

−286.8M USD

−232.7M USD

−18.9%

Cash

130.9M USD

171.4M USD

+30.9%

Shares outstanding

266.2M

266.2M

+0.0%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

—

100.0%

-12.5%

-27.8%

▼ 15 pts

Operating margin

—

-10583.1%

-2385.6%

-358.9%

▲ >999 pts

Net margin

—

-12272.3%

-2180.5%

-381.4%

▲ >999 pts

Return on assets (ROA)

-35.0%

-30.4%

-55.5%

-28.2%

-48.8%

▼ 21 pts

Return on equity (ROE)

-45.4%

-49.8%

-186.9%

-51.6%

-161.4%

▼ 110 pts

Free cash flow margin

—

-9221.0%

-2256.4%

-401.4%

▲ >999 pts

Current ratio

12.15×

9.18×

6.15×

10.88×

5.94×

▼ 45%

Quick ratio

—

6.15×

10.81×

5.48×

▼ 49%

Interest coverage

-127.65×

-16.10×

-3.99×

-25.98×

-7.38×

▲ 72%